OraSure TechnologiesOSUR
About: OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
Employees: 638
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
7% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 27
0% more funds holding
Funds holding: 187 [Q3] → 187 (+0) [Q4]
0.58% less ownership
Funds ownership: 90.2% [Q3] → 89.61% (-0.58%) [Q4]
8% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 63
16% less capital invested
Capital invested by funds: $287M [Q3] → $241M (-$45.8M) [Q4]
40% less call options, than puts
Call options by funds: $24K | Put options by funds: $40K
Research analyst outlook
We haven’t received any recent analyst ratings for OSUR.
Financial journalist opinion
Based on 4 articles about OSUR published over the past 30 days
